264 related articles for article (PubMed ID: 27999266)
1. Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae as Potential Candidates for the Treatment of Osteoporosis.
Qiu ZC; Dong XL; Dai Y; Xiao GK; Wang XL; Wong KC; Wong MS; Yao XS
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999266
[No Abstract] [Full Text] [Related]
2. Protective effects and network analysis of natural compounds obtained from Radix dipsaci, Eucommiae cortex, and Rhizoma drynariae against RANKL-induced osteoclastogenesis in vitro.
Cheng CF; Chien-Fu Lin J; Tsai FJ; Chen CJ; Chiou JS; Chou CH; Li TM; Lin TH; Liao CC; Huang SM; Li JP; Lin JC; Lin CC; Ban B; Liang WM; Lin YJ
J Ethnopharmacol; 2019 Nov; 244():112074. PubMed ID: 31291608
[TBL] [Abstract][Full Text] [Related]
3. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
4. Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts.
Kim JL; Kang SW; Kang MK; Gong JH; Lee ES; Han SJ; Kang YH
J Cell Biochem; 2012 Jan; 113(1):247-59. PubMed ID: 21898547
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Drynariae Rhizoma extracts on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts.
Jeong JC; Kang SK; Youn CH; Jeong CW; Kim HM; Lee YC; Chang YC; Kim CH
Int Immunopharmacol; 2003 Nov; 3(12):1685-97. PubMed ID: 14555293
[TBL] [Abstract][Full Text] [Related]
6. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Li L; Sapkota M; Kim SW; Soh Y
Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
[TBL] [Abstract][Full Text] [Related]
7. Enhanced osteoclastogenesis by mitochondrial retrograde signaling through transcriptional activation of the cathepsin K gene.
Guha M; Srinivasan S; Koenigstein A; Zaidi M; Avadhani NG
Ann N Y Acad Sci; 2016 Jan; 1364(1):52-61. PubMed ID: 25800988
[TBL] [Abstract][Full Text] [Related]
8. Interventional value of total flavonoids from Rhizoma Drynariae on Cathepsin K, a potential target of osteoporosis.
Shi XL; Liu K; Wu LG
Chin J Integr Med; 2011 Jul; 17(7):556-60. PubMed ID: 21725884
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory activity of Drynariae rhizoma extracts on cathepsin having bone resorption activity.
Jeong JC; Yoon CH; Jeong CW; Lee YC; Chang YC; Kim CH
Immunopharmacol Immunotoxicol; 2004 Aug; 26(3):373-85. PubMed ID: 15518171
[TBL] [Abstract][Full Text] [Related]
10. RANK ligand and interferon gamma differentially regulate cathepsin gene expression in pre-osteoclastic cells.
Pang M; Martinez AF; Jacobs J; Balkan W; Troen BR
Biochem Biophys Res Commun; 2005 Mar; 328(3):756-63. PubMed ID: 15694411
[TBL] [Abstract][Full Text] [Related]
11. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.
Lotinun S; Kiviranta R; Matsubara T; Alzate JA; Neff L; Lüth A; Koskivirta I; Kleuser B; Vacher J; Vuorio E; Horne WC; Baron R
J Clin Invest; 2013 Feb; 123(2):666-81. PubMed ID: 23321671
[TBL] [Abstract][Full Text] [Related]
12. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
13. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.
Balkan W; Martinez AF; Fernandez I; Rodriguez MA; Pang M; Troen BR
Gene; 2009 Oct; 446(2):90-8. PubMed ID: 19563866
[TBL] [Abstract][Full Text] [Related]
14. Effects of 1α,25-(OH)2D3 on the formation and activity of osteoclasts in RAW264.7 cells.
Gu J; Tong XS; Chen GH; Wang D; Chen Y; Yuan Y; Liu XZ; Bian JC; Liu ZP
J Steroid Biochem Mol Biol; 2015 Aug; 152():25-33. PubMed ID: 25864627
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis.
Helali AM; Iti FM; Mohamed IN
Curr Drug Targets; 2013 Dec; 14(13):1591-600. PubMed ID: 23957815
[TBL] [Abstract][Full Text] [Related]
16. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
17. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
Watanabe R; Okazaki R
Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
[TBL] [Abstract][Full Text] [Related]
18. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation.
Ang ES; Yang X; Chen H; Liu Q; Zheng MH; Xu J
FEBS Lett; 2011 Sep; 585(17):2755-62. PubMed ID: 21835177
[TBL] [Abstract][Full Text] [Related]
19. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
20. [Odanacatib (MK-0822)].
Nagase Y; Tanaka S
Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
